Notable Mover: A Reversal for Novartis AG (ADR) Is Not Near. The Stock Rises Again

Notable Mover: A Reversal for Novartis AG (ADR) Is Not Near. The Stock Rises Again

The stock of Novartis AG (ADR) (NYSE:NVS) is a huge mover today! About 1.27 million shares traded hands. Novartis AG (ADR) (NYSE:NVS) has risen 3.12% since March 11, 2016 and is uptrending. It has underperformed by 2.34% the S&P500.
The move comes after 5 months positive chart setup for the $197.91 billion company. It was reported on Oct, 14 by Barchart.com. We have $107.78 PT which if reached, will make NYSE:NVS worth $81.14B more.

Analysts await Novartis AG (ADR) (NYSE:NVS) to report earnings on October, 25. They expect $1.19 EPS, down 6.30% or $0.08 from last year’s $1.27 per share. NVS’s profit will be $3.08 billion for 16.06 P/E if the $1.19 EPS becomes a reality. After $1.22 actual EPS reported by Novartis AG (ADR) for the previous quarter, Wall Street now forecasts -2.46% negative EPS growth.

Novartis AG (ADR) (NYSE:NVS) Ratings Coverage

Out of 9 analysts covering Novartis Ag (NYSE:NVS), 2 rate it a “Buy”, 2 “Sell”, while 5 “Hold”. This means 22% are positive. Novartis Ag has been the topic of 13 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Chardan Capital Markets initiated the shares of NVS in a report on Tuesday, September 20 with “Buy” rating. Leerink Swann downgraded the shares of NVS in a report on Wednesday, March 23 to “Market Perform” rating. The stock of Novartis AG (ADR) (NYSE:NVS) earned “Underperform” rating by Mainfirst on Wednesday, October 28. On Friday, April 1 the stock rating was downgraded by UBS to “Neutral”. The company was initiated on Tuesday, April 5 by Argus Research. The stock of Novartis AG (ADR) (NYSE:NVS) has “Underperform” rating given on Tuesday, April 12 by Morgan Stanley. As per Monday, October 10, the company rating was maintained by Chardan Capital Markets. The stock of Novartis AG (ADR) (NYSE:NVS) has “Neutral” rating given on Tuesday, March 29 by Citigroup.

According to Zacks Investment Research, “Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders – their customers, their people, their shareholders and the communities in which they live and work.”

NVS Company Profile

Novartis AG, incorporated on March 1, 1996, is a holding company. The Firm specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s divisions include Pharmaceuticals, which researches, develops, makes, distributes and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines; Alcon, which operates through over three franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, makes and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment